Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN CLL-321: Pirtobrutinib vs Idelalisib + Rituximab or Bendamustine + Rituximab in BTK Inhibitor–Pretreated CLL/SLL
jRCT2021210031Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Loxo Oncology. Primary endpoint: Progression-free survival. Started Feb 2022; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2021210031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210031.